Patient characteristics
| Characteristic . | Total N = 105 . | CHIP . | P value . | |
|---|---|---|---|---|
| Positive n = 22 (21%) . | Negative n = 83 (79%) . | |||
| Age at diagnosis, median (range) | 68 (41-88) | 72 (51-88) | 67 (41-85) | .024∗ |
| Sex | ||||
| Female, n (%) | 42 (40) | 11 (50) | 31 (37.3) | .33 |
| Male, n (%) | 63 (60) | 11 (50) | 52 (62.6) | |
| Biochemical | ||||
| Beta-2 microglobulin (median), mg/L | 3.4 | 3.2 | 4.1 | .24† |
| Hemoglobin (median), g/dL | 11.5 | 10.7 | 11.8 | .056∗ |
| Mean corpuscular volume (median), fL | 91.7 | 90.6 | 91.9 | .29† |
| Monoclonal component (median), g/dL | 2.1 | 1.845 | 2.16 | .83† |
| Albumin (median), g/dL | 4 | 4 | 3.95 | .81† |
| Elevated lactate dehydrogenase (LDH), n (%) | 21 (20) | 3 (13.6) | 15 (18.1) | .55 |
| Cytopenias at diagnosis | ||||
| Leukopenia, n (%) | 27 (25.7) | 5 (22.7) | 22 (26.5) | .79 |
| Thrombocytopenia, n (%) | 11 (10.5) | 1 (4.5) | 10 (12) | .45 |
| Anemia, n (%) | 72 (68.6) | 17 (77.3) | 55 (66.3) | .44 |
| BM PC infiltrate (%) | 32 | 36.5 | 31 | .21† |
| Cytogenetics | .57 | |||
| Standard-risk, n (%) | 61 (58.1) | 12 (54.5) | 49 (59) | |
| High-risk, n (%) | 26 (24.7) | 7 (31.8) | 19 (22.9) | |
| na | 18 (17.1) | 3 (13.6) | 15 (18.1) | |
| ISS | ||||
| 1, n (%) | 47 (44.8) | 9 (40.9) | 38 (45.8) | .43 |
| 2, n (%) | 33 (31.4) | 6 (27.3) | 27 (32.5) | |
| 3, n (%) | 22 (20.9) | 7 (31.8) | 15 (18.1) | |
| na | 3 (2.9) | 0 | 3 (3.6) | |
| R-ISS | ||||
| 1, n (%) | 26 (24.8) | 6 (27.3) | 20 (24.1) | |
| 2, n (%) | 55 (52.4) | 9 (40.9) | 46 (55.4) | .049 |
| 3, n (%) | 12 (11.4) | 6 (27.3) | 6 (7.2) | |
| na | 12 (11.4) | 1 (4.5) | 11 (13.2) | |
| Cytopenias after first-line therapy | ||||
| Neutropenia, n (%) | 58 (55.2) | 12 (54.5) | 46 (55.4) | 1 |
| Thrombocytopenia, n (%) | 36 (34.3) | 9 (40.9) | 27 (32.5) | .61 |
| Anemia, n (%) | 85 (80.9) | 20 (90.9) | 65 (78.3) | .29 |
| na | 6 (5.7) | 1 (4.5) | 6 (6) | |
| Stem cell mobilization efficiency: harvested CD34+ cells (median), ×106/kg | 8 (4.1-14) | 7.6 (4.5-14) | 8.18 (4.1-14) | .77∗ |
| Neutrophil engraftment (days post-ASCT, median) | 12 | 11.5 | 12 | .78† |
| Platelet engraftment (days post-ASCT) | 17 | 17 | 17 | .86† |
| Characteristic . | Total N = 105 . | CHIP . | P value . | |
|---|---|---|---|---|
| Positive n = 22 (21%) . | Negative n = 83 (79%) . | |||
| Age at diagnosis, median (range) | 68 (41-88) | 72 (51-88) | 67 (41-85) | .024∗ |
| Sex | ||||
| Female, n (%) | 42 (40) | 11 (50) | 31 (37.3) | .33 |
| Male, n (%) | 63 (60) | 11 (50) | 52 (62.6) | |
| Biochemical | ||||
| Beta-2 microglobulin (median), mg/L | 3.4 | 3.2 | 4.1 | .24† |
| Hemoglobin (median), g/dL | 11.5 | 10.7 | 11.8 | .056∗ |
| Mean corpuscular volume (median), fL | 91.7 | 90.6 | 91.9 | .29† |
| Monoclonal component (median), g/dL | 2.1 | 1.845 | 2.16 | .83† |
| Albumin (median), g/dL | 4 | 4 | 3.95 | .81† |
| Elevated lactate dehydrogenase (LDH), n (%) | 21 (20) | 3 (13.6) | 15 (18.1) | .55 |
| Cytopenias at diagnosis | ||||
| Leukopenia, n (%) | 27 (25.7) | 5 (22.7) | 22 (26.5) | .79 |
| Thrombocytopenia, n (%) | 11 (10.5) | 1 (4.5) | 10 (12) | .45 |
| Anemia, n (%) | 72 (68.6) | 17 (77.3) | 55 (66.3) | .44 |
| BM PC infiltrate (%) | 32 | 36.5 | 31 | .21† |
| Cytogenetics | .57 | |||
| Standard-risk, n (%) | 61 (58.1) | 12 (54.5) | 49 (59) | |
| High-risk, n (%) | 26 (24.7) | 7 (31.8) | 19 (22.9) | |
| na | 18 (17.1) | 3 (13.6) | 15 (18.1) | |
| ISS | ||||
| 1, n (%) | 47 (44.8) | 9 (40.9) | 38 (45.8) | .43 |
| 2, n (%) | 33 (31.4) | 6 (27.3) | 27 (32.5) | |
| 3, n (%) | 22 (20.9) | 7 (31.8) | 15 (18.1) | |
| na | 3 (2.9) | 0 | 3 (3.6) | |
| R-ISS | ||||
| 1, n (%) | 26 (24.8) | 6 (27.3) | 20 (24.1) | |
| 2, n (%) | 55 (52.4) | 9 (40.9) | 46 (55.4) | .049 |
| 3, n (%) | 12 (11.4) | 6 (27.3) | 6 (7.2) | |
| na | 12 (11.4) | 1 (4.5) | 11 (13.2) | |
| Cytopenias after first-line therapy | ||||
| Neutropenia, n (%) | 58 (55.2) | 12 (54.5) | 46 (55.4) | 1 |
| Thrombocytopenia, n (%) | 36 (34.3) | 9 (40.9) | 27 (32.5) | .61 |
| Anemia, n (%) | 85 (80.9) | 20 (90.9) | 65 (78.3) | .29 |
| na | 6 (5.7) | 1 (4.5) | 6 (6) | |
| Stem cell mobilization efficiency: harvested CD34+ cells (median), ×106/kg | 8 (4.1-14) | 7.6 (4.5-14) | 8.18 (4.1-14) | .77∗ |
| Neutrophil engraftment (days post-ASCT, median) | 12 | 11.5 | 12 | .78† |
| Platelet engraftment (days post-ASCT) | 17 | 17 | 17 | .86† |